Introduction/Background General survival (GS) and clinical characteristics of the patients (NACT) undergoing interval debulking after neoadjuvant chemotherapy and the patients undergoing adjuvant chemotherapy after primary debulking surgery (PDS) were compared retrospectively among the patients with FIGO stage 3 and 4 ovarian carcinoma.

Methodology In this study, 141 patients who were diagnosed with FIGO stage 3 or 4 epithelial ovarian or fallopian tube carcinoma between 2009 and 2017 and had completed file data were included.

Results 73 (51.8%) patients and 68 (48.2%) patients were included in the in the NACT and PDS groups, respectively. 56 patients (81.2%) in the NACT group and 67 patients (98.5%) in the PDS group had an ECOG 0–1 performance score (p= 0.001). Average age was 60.4 ± 10 and 52.2 ± 10 years in the NACT and PDS groups, respectively (p<0.01). In the diagnosis, median CA 125 level was significantly higher in the NACT group than the PDS group (1068 vs 343 U/mL, p=0.01). When NACT and PDS groups were compared in the diagnosis in terms of the radiological stage, NACT group was more advanced stages (p<0.01). Complete resection (R0) rate in the PDC group was higher than the NACT group (80.9% (n=55) and 55% (n=33), p= 0.015, respectively). Among the patients younger than seventy years of age, median GS was statistically significantly higher in the PDS group than the NACT group (50 months vs 38 months, respectively), p<0.001].

Conclusion NACT group in this study, these patients were older, they had lower ECOG performance scores, and their CA 125 levels were higher. Unlike the randomized trials, this study is important in order to show the characteristics of the patient group sent to neoadjuvant therapy in ovarian cancer as well as the GS results in real life clinical practices.

Disclosure Nothing to disclose